Physician profile
Scarlet Constant
NPI 1497913131
$2,811.58
in general payments reported to CMS, 2019-2025
24 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $299 · 2021: $732 · 2022: $386 · 2023: $402 · 2024: $548 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $727.15 | 2023-2024 | Misight Contact Lens |
| Pfizer INC. | $520.36 | 2019-2025 | |
| Tris Pharma INC | $256.59 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $246.58 | 2020-2022 | |
| Glaxosmithkline, LLC. | $119.72 | 2019-2023 | Bexsero |
| Supernus Pharmaceuticals, INC. | $111.58 | 2021-2023 | Qelbree |
| Organon LLC | $88.55 | 2025 | Vtama |
| Ironshore Pharmaceuticals INC. | $87.14 | 2019-2022 | |
| Cranial Technologies, INC | $77.60 | 2019-2023 | Doc Band |
| Merck Sharp & Dohme LLC | $64.60 | 2021-2023 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Kaleo, INC. | $63.88 | 2020-2022 | |
| Corium, LLC | $62.66 | 2021-2023 | Azstarys |
| Adlon Therapeutics L.P. | $57.07 | 2021 | |
| Sanofi Pasteur INC. | $49.16 | 2019-2022 | |
| Genentech USA, INC. | $48.76 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43.17 | 2021 | |
| Seqirus USA INC | $36.37 | 2021-2022 | |
| Phadia US INC. | $33.97 | 2020-2021 | |
| Alk-Abello, INC | $22.52 | 2023 | Grastek, Ragwitek, Odactra |
| Collegium Pharmaceutical, INC. | $21.36 | 2025 | Jornay Pm |
| Shire North American Group INC | $20.82 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.29 | 2021 | |
| Galderma Laboratories, L.P. | $17.41 | 2022 | |
| Mission Pharmacal Company | $15.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scarlet Constant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.